Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Lymphoma

  Free Subscription


16.09.2019

1 Am J Hematol
2 Blood
2 BMC Cancer
1 Br J Dermatol
3 Br J Haematol
2 Cancer
1 Eur J Haematol
2 Int J Cancer
2 J Clin Oncol
4 Leuk Lymphoma
1 Leukemia


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Hematol

  1. MUNIR T, Brown JR, O'Brien S, Barrientos JC, et al
    Final analysis from RESONATE: up to 6 years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Am J Hematol. 2019 Sep 11. doi: 10.1002/ajh.25638.
    PubMed     Text format     Abstract available


    Blood

  2. IYER A, Hennessey D, O'Keefe S, Patterson J, et al
    Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma.
    Blood. 2019 Sep 12. pii: blood.2019002516. doi: 10.1182/blood.2019002516.
    PubMed     Text format     Abstract available


  3. Martin P, Bartlett NL, Blum KA, et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019;133(11):1201-1204.
    Blood. 2019;134:908.
    PubMed     Text format    


    BMC Cancer

  4. ZANELLI M, Zizzo M, Montanaro M, Gomes V, et al
    Fibrin-associated large B-cell lymphoma: first case report within a cerebral artery aneurysm and literature review.
    BMC Cancer. 2019;19:916.
    PubMed     Text format     Abstract available

  5. TAKASHIMA Y, Yoshimura T, Kano Y, Hayano A, et al
    Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells.
    BMC Cancer. 2019;19:910.
    PubMed     Text format     Abstract available


    Br J Dermatol

  6. MARONAS-JIMENEZ L, Estrach T, Gallardo F, Perez A, et al
    Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas.
    Br J Dermatol. 2017 Nov 18. doi: 10.1111/bjd.16128.
    PubMed     Text format     Abstract available


    Br J Haematol

  7. ADAMS HJA, Kwee TC
    Value of detecting bone marrow involvement in Hodgkin lymphoma.
    Br J Haematol. 2019 Sep 16. doi: 10.1111/bjh.16181.
    PubMed     Text format    

  8. ZANELLI M, Bertuzzi C, Zizzo M, Martino G, et al
    Extracavitary primary effusion lymphoma in a post-transplantation patient.
    Br J Haematol. 2019 Sep 13. doi: 10.1111/bjh.16196.
    PubMed     Text format    

  9. BAZARBACHI A, Boumendil A, Finel H, Castagna L, et al
    Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study.
    Br J Haematol. 2019 Sep 9. doi: 10.1111/bjh.16182.
    PubMed     Text format     Abstract available


    Cancer

  10. ABRAMSON JS, Irwin KE, Frigault MJ, Dietrich J, et al
    Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma.
    Cancer. 2019 Sep 10. doi: 10.1002/cncr.32411.
    PubMed     Text format    

  11. MAJOR A, Smith DE, Ghosh D, Rabinovitch R, et al
    Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis.
    Cancer. 2019 Sep 11. doi: 10.1002/cncr.32513.
    PubMed     Text format     Abstract available


    Eur J Haematol

  12. ATALLAH-YUNES SA, Murphy D, Abdelmalak R, Mantle L, et al
    Plasmablastic lymphoma achieving sustained remission with antiretroviral therapy alone.
    Eur J Haematol. 2019 Sep 10. doi: 10.1111/ejh.13326.
    PubMed     Text format     Abstract available


    Int J Cancer

  13. CHONG Y, Liu Y, Lu S, Cai B, et al
    Critical individual roles of the BCR and FGFR1 kinase domains in BCR-FGFR1-driven stem cell leukemia/lymphoma syndrome.
    Int J Cancer. 2019 Sep 16. doi: 10.1002/ijc.32665.
    PubMed     Text format     Abstract available

  14. PURDUE MP, Lan Q, Langseth H, Grimsrud TK, et al
    Pre-diagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes.
    Int J Cancer. 2019 Sep 15. doi: 10.1002/ijc.32684.
    PubMed     Text format     Abstract available


    J Clin Oncol

  15. ROSENWALD A, Bens S, Advani R, Barrans S, et al
    Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
    J Clin Oncol. 2019 Sep 9:JCO1900743. doi: 10.1200/JCO.19.00743.
    PubMed     Text format     Abstract available

  16. FUCHS M, Goergen H, Kobe C, Kuhnert G, et al
    Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
    J Clin Oncol. 2019 Sep 10:JCO1900964. doi: 10.1200/JCO.19.00964.
    PubMed     Text format     Abstract available


    Leuk Lymphoma

  17. TAPARRA K, Liu H, Polley MY, Ristow K, et al
    Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era.
    Leuk Lymphoma. 2019 Sep 13:1-11. doi: 10.1080/10428194.2019.1663419.
    PubMed     Text format     Abstract available

  18. WEI L, Wang J, Ye J, Yang L, et al
    Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study.
    Leuk Lymphoma. 2019 Sep 13:1-7. doi: 10.1080/10428194.2019.1663421.
    PubMed     Text format     Abstract available

  19. JOSHI M, Taper J, Forsyth C, Rowlings P, et al
    Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation.
    Leuk Lymphoma. 2019 Sep 12:1-7. doi: 10.1080/10428194.2019.1660968.
    PubMed     Text format     Abstract available

  20. THUMMALAPALLI R, Sena LA, Probasco JC, Gladstone DE, et al
    Checkpoint inhibitor-induced autoimmune encephalitis reversed by rituximab after allogeneic bone marrow transplant in a patient with Hodgkin lymphoma.
    Leuk Lymphoma. 2019 Sep 10:1-3. doi: 10.1080/10428194.2019.1658104.
    PubMed     Text format    


    Leukemia

  21. SONG Y, Gao Q, Zhang H, Fan L, et al
    Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.
    Leukemia. 2019 Sep 13. pii: 10.1038/s41375-019-0545.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: